periplocymarin has been researched along with Liver-Neoplasms* in 2 studies
2 other study(ies) available for periplocymarin and Liver-Neoplasms
| Article | Year |
|---|---|
Dual targets of lethal apoptosis and protective autophagy in liver cancer with periplocymarin elicit a limited therapeutic effect.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Cardiac Glycosides; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Mice; Mice, Nude | 2023 |
Redox-responsive PEGylated self-assembled prodrug-nanoparticles formed by single disulfide bond bridge periplocymarin-vitamin E conjugate for liver cancer chemotherapy.
Periplocymarin (PPM), a cardiac glycoside, has a narrow therapeutic index, poor tumor selectivity and severe cardiovascular toxicity which hinder its wide clinical applications in cancer treatment. Herein, we report novel redox-responsive prodrug-nanoparticles (MPSSV-NPs) self-assembled by co-nanoprecipitation of PPM-vitamin E conjugate and a PEG derivative of linoleate (mPEG2000-LA) in water. It was found that the characteristics of PPM-vitamin E nanoparticles (PSSV-NPs) were improved through co-nanoprecipitation with increased percentages of mPEG2000-LA. Moreover, the MPSSV-NPs were optimized according to the in vitro release and cytotoxicity study. Furthermore, the optimized MPSSV-NPs dramatically enhanced the circulation time and tumor distribution of PSSV-NPs after single intravenous injection. The in vivo studies in malignant H Topics: Animals; Cardiac Glycosides; Disulfides; Humans; Liver Neoplasms; Mice; Nanoparticles; Oxidation-Reduction; Prodrugs; Vitamin E | 2017 |